Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 26, 2023, regarding events occurring on October 20, 2023. Propanc Biopharma, Inc., a Delaware corporation with its principal executive office in Camberwell, Australia, entered into a material definitive agreement to secure financing.
Key Financial Metrics and Transaction Details
The filing details a specific financing transaction rather than periodic financial performance metrics. Key terms include:
- Instrument: Convertible Promissory Note.
- Principal Amount: $40,000.
- Interest Rate: 8% per annum (increases to 22% upon default).
- Maturity Date: October 20, 2024.
- Conversion Price: 65% of the average of the lowest three trading prices of Common Stock for the ten trading days immediately prior to conversion notice.
- Conversion Timing: Available to the investor at any time after 180 days from issuance.
- Beneficial Ownership Limitation: 4.99%.
- Reserve Requirement: Company must maintain a reserve of at least 500% of the number of Conversion Shares.
- Prepayment Terms: Company may prepay with a premium ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing within the first 180 days. No prepayment right exists after 180 days.
- Default Penalty: Upon an event of default, the outstanding amount becomes immediately due at 150% of the principal plus accrued interest.
Material Changes and Status
As of the filing date, the Company has not yet received the funds required to complete the transaction. The transaction is expected to close on or about October 27, 2023. The net proceeds are intended for general working capital purposes. The filing does not provide comparative financial data (revenue, profit, cash flow) as this is a current report on a specific event.
Guidance, Risks, and Covenants
Covenants: The Company agreed not to sell, lease, or dispose of all or substantially all of its assets outside the ordinary course of business (which would render it a "shell company") without the Investor's consent while the Note is outstanding.
Events of Default: Include failure to issue Conversion Shares, failure to maintain listing on an OTC market or equivalent, failure to comply with Exchange Act reporting requirements, insolvency, bankruptcy, or failure to pay principal and interest.
Risks: The high conversion discount (65%) and significant default penalty (150%) represent material dilution and liability risks. The prepayment premiums significantly increase the cost of early repayment.
Investor Verification Checklist
- Confirm the closing of the transaction and receipt of the $40,000 principal.
- Verify the Company's ability to maintain the required 500% share reserve for potential conversion.
- Monitor the Company's compliance with OTC market listing requirements to avoid default.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 4.1) for additional covenants.
- Assess the impact of potential conversion on existing shareholder equity given the 65% conversion price.